Abstract Factors that contribute to bone fragility in type 2 diabetes are not well understood. We assessed the effects of intensive glycemic control, thiazolidinediones (TZDs), and A 1C levels on bone geometry and strength at the radius and tibia. In a substudy of the Action to Control Cardiovascular Risk in Diabetes trial, peripheral quantitative computed tomographic (pQCT) scans of the radius and tibia were obtained 2 years after randomization on 73 participants (intensive n = 35, standard n = 38). TZD use and A 1C levels were measured every 4 months during the trial. Effects of intervention assignment, TZD use, and A 1C on pQCT parameters were assessed in linear regression models. Intensive, compared with standard, glycemic control was associated with 1.3 % lower cortical volumetric BMD at the tibia in men (p = 0.02) but not with other pQCT parameters. In women, but not men, each additional year of TZD use was associated with an 11 % lower polar strength strain index (SSIp) at the radius (p = 0.04) and tibia (p = 0.002) in models adjusted for A 1C levels. In women, each additional 1 % increase in A 1C was associated with an 18 % lower SSIp at the ultradistal radius (p = 0.04) in models adjusted for TZD use. There was no consistent evidence of an effect of intensive, compared with standard, glycemic control on bone strength at the radius or tibia. In women, TZD use may reduce bone strength at these sites. Higher A 1C may also be associated with lower bone strength at the radius, but not tibia, in women.
Introduction
Type 2 diabetes is associated with higher bone density but, paradoxically, with increased fracture risk. The reasons for this increased risk and the best approaches to fracture prevention in patients with diabetes are not clearly understood. In the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, intensive glycemic control did not reduce fracture risk compared with standard control [1] . There was also no difference in bone loss as measured by dual-energy X-ray absorptiometry (DXA) in the two trial groups. However, the intensive therapy was characterized by greater use of thiazolidinediones (TZDs), known to increase fracture risk in women and possibly in men [2] [3] [4] [5] [6] [7] . TZDs have also been shown to increase bone loss at the hip and spine in shortterm trials based on DXA [2] , but studies of the effects at peripheral skeletal sites are not available. Reports on the relationship between A 1C and bone density by DXA at the hip and spine are conflicting [8, 9] . A meta-analysis of A 1C and forearm BMD by DXA reported a trend toward lower BMD with higher A 1C , but the result, based on only four studies, was not statistically significant [9] . Information is not available on the effects of glycemic control on the separate compartments of cortical and trabecular bone.
To better understand the effect of the intensive glycemic control intervention on bone and to assess the separate effects of TZD use and improved A 1C , we used data from peripheral quantitative computed tomographic (pQCT) scans of the radius and tibia obtained on a subset of ACCORD participants. pQCT scans provide volumetric and geometric parameters that cannot be obtained from DXA scans, allowing separate assessment of trabecular and cortical bone and of estimated strength.
Subjects and Methods

ACCORD Trial Design and Participants
The ACCORD trial has been described previously [10] . Briefly, inclusion criteria for participants included type 2 diabetes, an A 1C of 7.5-11 %, age 40-79 years with a history of cardiovascular disease (CVD) or 55-79 years with subclinical evidence of CVD or significant risk factors for CVD. Exclusion criteria included frequent serious hypoglycemia, body mass index of 45 kg/m 2 or more, serum creatinine above 1.5 mg/dL (132.6 lmol/L), or other serious illness. The trial included 77 clinical sites in the United States and Canada.
ACCORD was a double two-by-two factorial, parallel treatment trial. All eligible participants (n = 10,251) were randomly assigned to the intensive or standard glycemia group, with A 1C goals of \6 and 7.0-7.9 %, respectively. Participants were also assigned to either the blood pressure or lipid trial, based on eligibility. During the trial, ACCORD achieved a median A 1C of 6.4 and 7.5 % in the intensive and standard glycemia groups, respectively. Participants in both arms of the trial received individualized therapeutic plans that increased the number and dose of diabetes medications (metformin, sulfonylureas, TZDs, insulin, and other medications) as needed to achieve the specified A 1C goal for that arm [11] . The intensive glycemia intervention protocol was stopped in February 2008 because of higher all-cause mortality in those assigned to this treatment strategy [11] . All participants were transferred to the standard glycemia therapy. The trial concluded in June 2009.
pQCT Ancillary Study
At five clinical sites in the Minneapolis area, pQCT scans of the radius and tibia were obtained on a subgroup of consenting participants (n = 73) at the 2-year visit. The scans were obtained within 3 months of the close of the intensive glycemia arm. Sixteen participants were scanned before the close (average 18 days, range 1-30 days), and 57 participants were scanned after the close (average 46 days, range 4-90 days). Institutional review boards at participating institutions approved the protocol for the pQCT ancillary study, and written informed consent was obtained from all participants.
pQCT (XCT-3000; Stratec, Pforzheim, Germany) was used to obtain slices (2.3 ± 0.2 mm) at the 4, 33, and 66 % sites of the left tibia and the 4 and 33 % sites of the nondominant radius. Scans were obtained using a 0.5 mm voxel size and a scan speed of 30 mm/s. Slices were taken as a percentage of the limb length from the distal end of the relevant bone. Anatomic reference lines for the tibia (distal edge of the tibial plafond) and the radius (distal radius joint surface) were determined by acquisition of a 30-mm planar scout view of the joint line. Quality assurance was performed by daily scanning of a manufacturer-provided anthropometric phantom.
Image data were analyzed according to the manufacturer's specifications. Scans at the 4 % (radius and tibia) sites include predominantly trabecular bone, while scans at the 33 % (radius and tibia) and 66 % (tibia) sites include predominantly cortical bone. At the ultradistal trabecular (4 %) sites, Contour mode 2 (169 mg/cm 3 ) and Peel mode 1 (45 % area) were used. Ultradistal sites were assessed for total and trabecular bone cross-sectional area (mm 2 ) and volumetric density (mg/mm 3 ). As an index of bone compressive strength, bone strength index (BSI, mg/mm to the fourth) was calculated as (ToA 9 ToD 2 )/1,000,000, where ToA is total bone area and Tod is total bone density. At the predominantly cortical radius (33 %) and tibia (33 and 66 %) sites, whole-bone properties were determined using Contour mode 2 (169 mg/cm 3 ) and cortical bone properties, using Cort mode 1 (710 mg/cm 3 ). A threshold of 280 mg/cm 3 was used to determine the polar strength strain index (SSIp). Predominantly cortical site variables included cross-sectional area (mm 2 ), cortical area (mm 2 ), cortical thickness (mm), endosteal and periosteal diameter (mm), cortical bone mineral content (BMC, mg/mm), and cortical bone volumetric density (mg/mm 3 ). Section modulus (mm 3 ) and SSIp (mm 3 ) were calculated as estimates of bone strength [12] . Section modulus is a measure of bone strength based on only bone geometry [13] , and SSIp is a ''density-weighted'' section modulus value, which incorporates cortical density into the strength measure.
TZD Use in ACCORD
Rosiglitazone was included in the original treatment algorithm for the intensive and standard glycemia therapy groups, and pioglitazone was added in the fall of 2007. Participants attended clinic visits every 2-4 months. For each clinic visit, staff recorded the participant's use of diabetes medications, including TZDs, at visit entry and the prescribed medications at visit exit. Doses of oral medications were not systematically recorded. During the ACCORD trial, 92 % of the intensive glycemia group and 58 % of the standard glycemia group were prescribed a TZD [11] . ''Cumulative days of TZD use'' from baseline to the pQCT scans was calculated for each participant, using data from ACCORD visits starting with the first visit after randomization and continuing to the last visit before the scans. ''Time since last TZD use'' was calculated as the number of days from the last reported TZD use to the pQCT scans. 
Statistical Analyses
Linear regression models were used to assess the effects of assignment to the intensive glycemic control group compared to the standard control group on pQCT outcomes. As required for the ACCORD primary analyses, we adjusted for the presence of CVD at baseline, assignment to either the blood-pressure trial or the lipid trial, and randomized treatment assignments in the blood-pressure and lipid trials.
The associations of cumulative TZD use and average A 1C during ACCORD with pQCT outcomes were estimated using linear models with adjustment for baseline TZD use, baseline A 1C , and age. Regression effects are presented as the difference in the average value of each pQCT outcome per unit change in TZD use or average A 1C , as a percent of the mean of that outcome. Because TZD use is more clearly associated with increased fracture risk in women, these models were estimated separately for men and women.
Statistical significance was set at p \ 0.05 and was not adjusted for multiple comparisons. These are hypothesisgenerating analyses, designed to identify areas for future research. Given this objective and the small sample size, we focused on limiting the risk of Type II errors and have interpreted the results accordingly. Analyses were performed in SAS 9.2 (SAS Institute, Cary, NC).
Results
At ACCORD randomization, the 73 participants in the pQCT substudy included 48 men and 25 women (Table 1) . Among these participants, 35 were randomized to the intensive and 38 to the standard glycemic control intervention. Average age was 62.1 years, and average A 1C at baseline was 8.1 %. From baseline to the pQCT scan, use of osteoporosis or hormone therapy was reported by three participants and use of oral steroids, by one participant.
Intensive Glycemic Control
There were no statistically significant differences in pQCT parameters among women, comparing those assigned to intensive and standard glycemic control ( Table 2 ). In men, cortical volumetric BMD (vBMD) at the 33 % tibia was lower in those randomized to intensive glycemic control (-1.3 %, p = 0.045), but none of the other parameters were statistically different (Table 3) .
TZD Use
Between randomization and the pQCT scans, 52 participants used rosiglitazone and three of these participants also used pioglitazone. Among those who used a TZD, mean use from randomization to the pQCT scans was 655 days. In models for women, adjusted for average A 1C during ACCORD prior to the pQCT scans, greater cumulative TZD use was associated with several indicators of lower bone strength. SSIp was lower at all sites, but the differences were statistically significant only at the 33 % radius and 66 % tibia (Table 4 ). Other indicators of bone strength that were reduced with greater TZD use were as follows: at 33 % radius, lower total BMC, cortical BMC, and cortical bone area; at 33 % tibia, lower total bone area and periosteal diameter; at 66 % tibia, lower total bone area, periosteal diameter, and section modulus. Other parameters were not statistically different by TZD use (Table 4) . Among men (n = 48), none of the pQCT parameters differed (p \ 0.05) by cumulative TZD use in adjusted models.
Average A 1C
The median value for average A 1C in ACCORD before the pQCT scan was 6.4 % in the intensive and 7.4 % in the standard glycemia therapy group. In models adjusted for cumulative TZD use during ACCORD prior to the pQCT scans, average A 1C in women was associated with deficits in several pQCT parameters for the radius at pQCT-V1: at the 33 % radius, total vBMD, cortical BMC, cortical bone area, cortical thickness, and endosteal diameter; at the 4 % radius, SSIp (Table 5 ). There were no statistically significant associations between average A 1C and pQCT parameters at the tibia in women. In men, there were no statistically significant associations with average A 1C at either site.
Discussion
Intensive glycemic control in ACCORD was not associated with consistent differences in bone density or strength, measured near the close of the intensive glycemia group after about 2 years of the intervention. These null findings for intensive glycemic control are consistent with our previous report that intensive control was not associated with increased fracture risk or with bone loss by DXA in ACCORD [15] . However, participants in the intensive glycemic control group had more TZD use, with potential negative effects on bone, which may have blunted any positive effect of improved A 1C levels. When we explored this hypothesis in observational analyses, we found evidence that TZD use in women may be associated with deficits in bone strength and geometry at the radius and tibia, while lower average A 1C levels in women may be associated with improved parameters at the radius. Our observational results suggest that, at least in women, the combination of greater TZD use with lower A 1C levels in the intensive glycemic control group may have resulted in little net effect on bone and may account for the lack of difference in bone parameters between the two treatment groups. This is the first report on TZD and A 1C effects on bone measured with pQCT.
We found evidence that TZD use in women was associated with reduced strength at the radius and tibia, particularly at the highly cortical sites (33 % radius, 33 and 66 % tibia). Differences with TZD use were not evident for trabecular or cortical vBMD but were seen in SSIp, a derived measure of bone strength that takes into account bone geometry and cortical density. SSIp has been shown to predict failure load in cadaveric studies [16] , to discriminate between those with and without vertebral fracture [17] , and to predict incident nonvertebral fractures [18] .
Reduced strength with longer duration of TZD use was evident in models adjusted for achieved A 1C levels during ACCORD. In other words, among women with a similar A 1C level, those with greater TZD use tended to have reduced bone strength. These results suggest that TZD use may have a positive effect on bone strength by improving A 1C levels but may also have a negative effect on bone through other pathways. Rodent models indicate that one other pathway may be through peroxisome proliferatoractivated receptor-gamma activation, causing decreased osteoblastogenesis and increased marrow adipogenesis [19] .
Previous studies have not examined the effect of TZDs on bone density or strength in the peripheral skeleton. However, trials and observational studies have provided evidence of more rapid bone loss at the hip and spine in women, using DXA [20] [21] [22] [23] [24] and, in one trial, QCT of the hip and spine [25] . The QCT results indicated that rosiglitazone, compared with metformin, was associated with greater losses of trabecular bone at the hip and spine over 12 months. Losses in cortical bone, measured at the hip, were not statistically different. In rodent models, increased loss of trabecular bone and whole-bone density has been reported with rosiglitazone [19] and pioglitazone treatment [26] . Recently, studies in rodents have also reported deficits in cortical bone with TZDs, including increased cortical porosity [27] and reduced cortical thickness [28, 29] . Consistent with our finding of reduced bone strength at the radius and tibia with TZD use, reports from trials and observational studies indicate that women have an increased risk of fractures with TZD use [2-7, 30, 31] . Clinical trials have demonstrated an increased risk of peripheral fractures in particular with TZD use. Trials lacked adequate numbers of hip and spine fractures to Table 2 Peripheral QCT bone parameters in women (n = 988 (118) 928 (140) 374 (86) 350 (87) 598 (147) 625 (126) 860 (109) 853 (98) 303 (51) 297 (62) BMC (mg/mm) 94 (15) 92 (18) 92 (13) 89 (15) 320 (52) 339 (49) 287 (31) 302 (31) 265 (33) 279 (44) Bone area (mm 2   ) 97 (17) 100 (18) 254 (52) 264 (55) 549 (76) 555 (97) 336 (29) 357 (48) 888 ( (26) 1,159 (34) 1,144 (18) BMC (mg/mm) 92 (15) 88 (18) 267 (66) 291 (53) 278 (43) 284 (30) Area (mm   2   ) 78 (11) 76 (15) 246 (52) 268 (45) 239 (34) 248 (28) Thickness (mm) 3 (0.6)
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35 (3) 35 (3) 83 (6) 83 (7) 65 (3) 67 (5) 105 (8) 110 (10) Endosteal diameter (mm)
14 (6) 18 (5) 61 (12) 59 (11) 36 (7) 36 (7) Strength indices SSIp (mm   3   ) 213 (44) 228 (48) 330 (75) 318 ( 192 (50) 236 (35) 236 (49) BMC (mg/mm) 23 (5) 22 (5) 94 (18) 100 (17) Area (mm   2   ) 114 (24) 119 (25) 399 (60) 434 (84) Compressive BSI (mg 35 (9) 32 (13) 81 (19) 84 (26) Mean (SD). p 964 (118) 982 (78) 351 (66) 375 (66) 639 (79) 651 (69) 897 (66) 921 (52) 321 (45) 324 (30) BMC (mg/mm)
148 (34) 145 (17) 153 (34) 154 (21) 475 (58) 482 (56) 415 (47) 428 (53) 398 (67) 407 (51) Bone area (mm 2   ) 161 (76) 148 (20) 447 (116) 421 (87) 751 (106) 746 (96) 464 (52) 467 ( 139 (25) 139 (17) 412 (59) 418 (60) 394 (48) 410 (52) Area (mm   2   ) 119 (21) 118 (14) 380 (49) 383 (52) 343 (41) 353 (48) Thickness ( 44 (8) 43 (3) 97 (7) 97 (6) 76 (4) 76 (5) 125 (13) 126 (8) Endosteal diameter (mm)
21 (11) 19 (4) 68 (9) 67 (7) 39 (5) 38 (5) Strength indices SSIp (mm 214 (32) 242 (32) 241 (31) BMC (mg/mm)
43 (18) 40 (10) 138 (32) 138 ( 54 (19) 58 (13) 128 (31) 132 (23) Bold values indicate p assess risks, but observational studies indicate that TZD use also increases fracture risk at these sites [3, 4, 7, 30, 31] . We did not find any consistent pattern of increased bone loss with TZD use in men. In the only trial that has examined the effect of TZD use on bone in men, an 80-week randomized trial comparing rosiglitazone plus metformin with metformin alone, addition of rosiglitazone was associated with increased bone loss at the total hip in men [24] . Previous observational studies have been inconsistent regarding effects on bone density in men [20, 32] . In clinical trials reporting fracture events TZD use has not been associated with increased risk in men [2] , but some observational studies have reported increased fracture risk with TZD use in men [3] [4] [5] [6] [7] .
We found evidence of deficits in cortical bone at the radius with higher A 1C in women. Previous studies of glycemic control and peripheral bone density are limited. In a metaanalysis, Ma et al. [9] found no statistically significant association between A 1C and forearm BMD by DXA in type 2 diabetes. For spine and hip BMD, however, this meta-analysis reported a positive association between A 1C levels and BMD. On the other hand, a meta-analysis by Vestergaard [8] found no relationship between A 1C and hip or spine BMD. In a longitudinal study of the effects of improved glycemic control on bone, patients with initial poor control (mean A 1C 11.6 %) had improvements in spine and hip BMC, measured by DXA, after 1 year of adequate control [33] .
Hyperglycemia may contribute to bone fragility through effects on bone cells. In rodent models, hyperglycemia is associated with reduced differentiation of osteoblasts and increased marrow fat, suggesting that stem cell lineage may favor adipogenesis over osteoblastogenesis with high glucose levels [34] . Consistent with this hypothesis, Baum et al. [35] reported that A 1C levels are positively correlated with vertebral marrow fat in women with type 2 diabetes. Higher A 1C levels are positively correlated with sclerostin, a product of osteocytes that inhibits bone formation [36] , in patients with type 2 diabetes [37] . Osteocyte function is crucial for bone to respond to mechanical loading signals with appropriate increases in size and density [38] . Hyperglycemia may also affect bone through increases in microangiopathy, peripheral neuropathy, and decreased renal function, factors that are associated with lower bone density [39] [40] [41] . These findings raise the possibility that lower A 1C levels may contribute to skeletal health in diabetes, possibly through maintenance of osteocyte and osteoblast function. In ACCORD, lower A 1C levels were achieved with a high rate of TZD use, in both the standard and intensive control groups [11] . The negative effects of TZDs on bone, particularly in women, may have offset any gains from lowering A 1C in the intensive glycemia treatment group, resulting in a lack of differences in bone parameters between the intensive and standard glycemia groups. Additional research is needed to ascertain whether improved glycemic control achieved without use of TZDs has a positive effect on bone health.
The randomized trial design of ACCORD provides an optimal setting for comparing the effects of intensive and standard glycemic control on bone parameters. However, pQCT scans were obtained about 2 years after randomization. Measurements at baseline would have provided more power to detect a difference by treatment group. Because of randomization, baseline characteristics in ACCORD, including pQCT parameters, will generally be similar across treatment assignments. The baseline factors that we considered were similarly distributed across treatment arms in the pQCT subgroup (Table 1) . However, baseline differences in pQCT parameters are possible due to chance in this randomized design.
The comparison of the effects of intensive and standard glycemic control is necessarily limited to the ACCORD algorithms for achieving control, an approach that included substantial TZD use. Another limitation is the small number of participants included in this substudy. Along with the lack of a baseline measurement, this reduced the power of the study to detect effects of intensive glycemic control on pQCT parameters, limiting our ability to interpret negative findings. This study also included multiple comparisons, increasing the possibility of Type I errors. Our examination of the contributions of A 1C levels and TZD use to bone parameters is an observational crosssectional analysis subject to potential confounding. Thus, our results for the effects of TZD use and A 1C levels must be considered hypothesis-generating, requiring cautious interpretation and confirmation in other settings.
In conclusion, 2 years of intensive, compared with standard, glycemia therapy among patients with type 2 diabetes in the ACCORD trial had little effect on bone strength or geometry at the radius and tibia. In women, TZD use may have detrimental effects on bone strength, particularly cortical bone, at peripheral skeletal sites. Although intensive glycemic control was not associated with differences in bone strength, higher A 1C levels may be associated with lower bone strength at the radius in women independently of TZD use. These preliminary findings need to be tested in larger studies.
